Top 3 Trends for Angina Pectoris Drugs Market by Technavio

Technavio has published a new report on the global angina pectoris drugs market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio’s latest report on the global angina pectoris drugs market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Angina is a type of chest pain or discomfort caused due to a coronary heart disease, mainly due to the reduced oxygen-rich blood flow to the heart. The heart needs oxygen to function; blood is responsible for carrying and delivering oxygen throughout the body. Angina may increase the risk of heart attack. It can be further divided into unstable and stable angina.

Sapna Jha, a lead analyst from Technavio, specializing in research on cardiovascular and metabolic disorders sector, says, “Changes in the lifestyle of a person can greatly help prevent future episodes of angina pectoris. The changes may include regular exercise, healthy diet. Quitting smoking is also suggested for smokers. It also includes managing chronic diseases such as high blood pressure, high cholesterol, and diabetes as these conditions may lead to heart disease.”

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

The top three emerging trends driving the global angina pectoris drugs market according to Technavio research analysts are:

  • Launch of novel pharmacologic agents
  • Genomic medicines
  • Growing strategic alliances

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Launch of novel pharmacologic agents

There has been a continuous unmet demand for therapeutics in the angina pectoris drugs market. This, in turns, paves the way for the entry of novel therapeutic agents in the market. Along with traditional therapeutic agents, trimetazidine, ivabradine, fasudil, and ranolazine represent a promising new therapeutic approach for the treatment of angina pectoris.

“The angina pectoris drugs can be used by the patients who are intolerant to beta-blockers or for whom beta-blockers are contraindicated. Trimetazidine decreases fatty acid oxidation and improves the biochemical efficiency of cardiac myocyte at the time of ischemia, it represents a promising approach for the treatment of angina pectoris,” according to Sapna.

Genomic medicines

Genomics involves the study of genomes, the complete set of genetic material within any organism. Genomic medicine is an emerging field in healthcare, which uses gene based information such as sequencing and placing of a patient to help doctors in making better diagnostic and therapeutic decisions.

Based on growing prevalence and the lack of adequate approved therapy for the treatment, genomic medicine is expected to fuel the overall cardiovascular treatment space, including the angina pectoris drugs market. As the medical world is increasingly focusing on regenerative medicine, primarily due to its least side effects, the advent of genomic medicine is expected to witness wide adoption among patients and medical practitioners.

Growing strategic alliances

The market has been witnessing a growing trend of strategic alliances and acquisitions where players with strong cash position either buyout the desired molecule or the entire firm. Vendors also form joint ventures for drug development or enter into partnership or out-license the marketing or manufacturing rights for various drugs.

AstraZeneca acquired ZS Pharma, a specialty biopharmaceutical company with a strong product pipeline in cardiovascular space. AstraZeneca expects the acquisition to bolster its already strong cardiovascular and metabolic disorders portfolio further. Such initiatives will increase the business activities of vendors, thereby driving the market growth.

The key vendors are as follows:

  • AstraZeneca
  • Gilead
  • Novartis
  • Pfizer

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio’s report on the global angina pectoris drugs market provides an analysis of the most important trends expected to impact the market outlook.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200